<p>Acorn Capital Advisors LLC 在最近向 SEC 提交的文件中表示，在第一季度其在 Y-mAbs Therapeutics, Inc.（NASDAQ:YMAB - 免费报告）的持股增加了 13.1%。该基金在本季度额外购买了 373,562 股后，持有该公司 3,235,387 股股票。Y-mAbs Therapeutics 占 Acorn Capital Advisors LLC 投资组合的 9.3%，是其第三大持股。截至最近的 SEC 文件，Acorn Capital Advisors LLC 持有 Y-mAbs Therapeutics 约 7.14% 的股份，价值 14,333,000 美元。</p>
<ul>
<li>2023 年初的裁员将如何影响这 5 只生物科技股票？</li>
</ul>
<p>其他一些对冲基金也对 YMAB 的持仓进行了调整。Infinitum Asset Management LLC 在第四季度购买了价值约 1,218,000 美元的 Y-mAbs Therapeutics 新股份。Paradigm Biocapital Advisors LP 在第四季度将其在 Y-mAbs Therapeutics 的持股增加了 3.7%。Paradigm Biocapital Advisors LP 现在持有 4,236,346 股该公司的股票，价值 33,171,000 美元，此前在最后一个季度又购买了 150,000 股。AQR Capital Management LLC 在第一季度将其在 Y-mAbs Therapeutics 的持股增加了 869.3%。AQR Capital Management LLC 现在持有 164,788 股该公司的股票，价值 730,000 美元，此前在最后一个季度又购买了 147,788 股。Stonepine Capital Management LLC 在第一季度购买了价值约 581,000 美元的 Y-mAbs Therapeutics 新股份。最后，Nuveen LLC 在第一季度购买了价值约 498,000 美元的 Y-mAbs Therapeutics 新股份。对冲基金和其他机构投资者持有该公司 70.85% 的股票。</p>
<p>获取 <strong>Y-mAbs Therapeutics</strong> 的提醒：</p>
<h2>Y-mAbs Therapeutics 股票上涨 0.1%</h2>
<p>NASDAQ:YMAB 周五开盘价为 8.55 美元。该股票的 50 日移动平均价格为 6.05 美元，200 日移动平均价格为 5.20 美元。该公司的市值为 3.8851 亿美元，市盈率为-17.10，贝塔值为 0.57。Y-mAbs Therapeutics, Inc.的 52 周低点为 3.55 美元，52 周高点为 16.11 美元。</p>
<p>Y-mAbs Therapeutics（NASDAQ:YMAB - 获取免费报告）最近一次发布季度财报是在 8 月 8 日，周五。该公司报告的每股收益为（0.07 美元），超出分析师一致预期的（0.27 美元）0.20 美元。Y-mAbs Therapeutics 的股本回报率为-24.60%，净利润率为-26.03%。该公司在本季度的收入为 1952 万美元，而分析师的预期为 1840 万美元。整体来看，卖方分析师预计 Y-mAbs Therapeutics, Inc.在当前财政年度将发布-0.65 的每股收益。</p>
<h2>华尔街分析师的看法</h2>
<p>一些研究公司最近对 YMAB 发表了评论。Oppenheimer 在 8 月 5 日的报告中将 Y-mAbs Therapeutics 的评级从 “跑赢大盘” 下调至 “市场表现”。HC Wainwright 在 8 月 6 日的报告中重申了 “中性” 评级，并对 Y-mAbs Therapeutics 的股票设定了 8.60 美元的目标价（之前为 11.00 美元）。摩根士丹利在 8 月 5 日的研究报告中对 Y-mAbs Therapeutics 设定了 8.60 美元的目标价。Jones Trading 在 8 月 5 日的研究报告中将 Y-mAbs Therapeutics 的评级从 “强烈买入” 下调至 “持有”。最后，Cantor Fitzgerald 在 8 月 5 日的研究报告中对 Y-mAbs Therapeutics 设定了 8.60 美元的目标价，并给予该股票 “中性” 评级。八位股票研究分析师对该股票给予了 “持有” 评级，两位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “减持”，平均目标价为 9.62 美元。</p>
<p><strong>获取我们对 Y-mAbs Therapeutics 的最新股票分析</strong></p>
<h2>关于 Y-mAbs Therapeutics</h2>
<p>（免费报告）</p>
<p>Y-mAbs Therapeutics, Inc.是一家商业阶段的生物制药公司，专注于开发和商业化抗体基础的治疗产品，以治疗美国及国际上的癌症。它提供 DANYELZA，一种与粒细胞 - 巨噬细胞集落刺激因子联合使用的单克隆抗体，用于治疗骨髓或骨中复发或难治性高风险神经母细胞瘤的儿童患者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Y-mAbs Therapeutics</li>
<li>如何从成长投资中获利</li>
<li>MarketBeat 周回顾 – 08/25 - 08/29</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>改善基本面推动三只强劲表现者的新回购</li>
<li>英国市场假期是什么？如何投资和交易</li>
<li>Gartner 可能是第三季度最佳买入的三个理由</li>
</ul>
<p><strong>想看看其他对冲基金持有 YMAB 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Y-mAbs Therapeutics, Inc.（NASDAQ:YMAB - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WU1BQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WU1BQg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Y-mAbs Therapeutics 吗？</h2>
<p>在考虑 Y-mAbs Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场意识到之前……而 Y-mAbs Therapeutics 并不在名单上。</p>
<p>虽然 Y-mAbs Therapeutics 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票的详情</p>

YMAB

<p>Acorn Capital Advisors LLC 在第一季度将其在 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) 的持股增加了 13.1%，目前持有 3,235,387 股，成为其投资组合中第三大持股。其他对冲基金也调整了他们的持仓，机构投资者持有该股票的 70.85%。Y-mAbs Therapeutics 报告了上个季度的收入为 1952 万美元，超出预期。分析师对该股票的评级不一，平均目标价为 9.62 美元，普遍评级为 “减持”</p>

<p>Acorn Capital Advisors LLC grew its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 13.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,235,387 shares of the company's stock after acquiring an additional 373,562 shares during the quarter. Y-mAbs Therapeutics comprises 9.3% of Acorn Capital Advisors LLC's investment portfolio, making the stock its 3rd biggest holding. Acorn Capital Advisors LLC owned about 7.14% of Y-mAbs Therapeutics worth $14,333,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Acorn Capital Advisors LLC 在最近向 SEC 提交的文件中表示，在第一季度其在 Y-mAbs Therapeutics, Inc.（NASDAQ:YMAB - 免费报告）的持股增加了 13.1%。该基金在本季度额外购买了 373,562 股后，持有该公司 3,235,387 股股票。Y-mAbs Therapeutics 占 Acorn Capital Advisors LLC 投资组合的 9.3%，是其第三大持股。截至最近的 SEC 文件，Acorn Capital Advisors LLC 持有 Y-mAbs Therapeutics 约 7.14% 的股份，价值 14,333,000 美元。</p>
</div><ul>
<li>How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>2023 年初的裁员将如何影响这 5 只生物科技股票？</li>
</ul>
</div><p>A number of other hedge funds have also made changes to their positions in YMAB. Infinitum Asset Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $1,218,000. Paradigm Biocapital Advisors LP increased its holdings in shares of Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after acquiring an additional 150,000 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Y-mAbs Therapeutics by 869.3% in the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after acquiring an additional 147,788 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $581,000. Finally, Nuveen LLC purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $498,000. Hedge funds and other institutional investors own 70.85% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金也对 YMAB 的持仓进行了调整。Infinitum Asset Management LLC 在第四季度购买了价值约 1,218,000 美元的 Y-mAbs Therapeutics 新股份。Paradigm Biocapital Advisors LP 在第四季度将其在 Y-mAbs Therapeutics 的持股增加了 3.7%。Paradigm Biocapital Advisors LP 现在持有 4,236,346 股该公司的股票，价值 33,171,000 美元，此前在最后一个季度又购买了 150,000 股。AQR Capital Management LLC 在第一季度将其在 Y-mAbs Therapeutics 的持股增加了 869.3%。AQR Capital Management LLC 现在持有 164,788 股该公司的股票，价值 730,000 美元，此前在最后一个季度又购买了 147,788 股。Stonepine Capital Management LLC 在第一季度购买了价值约 581,000 美元的 Y-mAbs Therapeutics 新股份。最后，Nuveen LLC 在第一季度购买了价值约 498,000 美元的 Y-mAbs Therapeutics 新股份。对冲基金和其他机构投资者持有该公司 70.85% 的股票。</p>
</div><p>Get <strong>Y-mAbs Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Y-mAbs Therapeutics</strong> 的提醒：</p>
</div><h2>Y-mAbs Therapeutics Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Y-mAbs Therapeutics 股票上涨 0.1%</h2>
</div><p>NASDAQ:YMAB opened at $8.55 on Friday. The stock's 50 day moving average price is $6.05 and its 200 day moving average price is $5.20. The company has a market capitalization of $388.51 million, a PE ratio of -17.10 and a beta of 0.57. Y-mAbs Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $16.11.</p>
<div class="lb-trans"><p>NASDAQ:YMAB 周五开盘价为 8.55 美元。该股票的 50 日移动平均价格为 6.05 美元，200 日移动平均价格为 5.20 美元。该公司的市值为 3.8851 亿美元，市盈率为-17.10，贝塔值为 0.57。Y-mAbs Therapeutics, Inc.的 52 周低点为 3.55 美元，52 周高点为 16.11 美元。</p>
</div><p>Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%.The company had revenue of $19.52 million during the quarter, compared to analysts' expectations of $18.40 million. As a group, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Y-mAbs Therapeutics（NASDAQ:YMAB - 获取免费报告）最近一次发布季度财报是在 8 月 8 日，周五。该公司报告的每股收益为（0.07 美元），超出分析师一致预期的（0.27 美元）0.20 美元。Y-mAbs Therapeutics 的股本回报率为-24.60%，净利润率为-26.03%。该公司在本季度的收入为 1952 万美元，而分析师的预期为 1840 万美元。整体来看，卖方分析师预计 Y-mAbs Therapeutics, Inc.在当前财政年度将发布-0.65 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of research firms have recently commented on YMAB. Oppenheimer downgraded Y-mAbs Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Tuesday, August 5th. HC Wainwright reiterated a &#34;neutral&#34; rating and issued a $8.60 price objective (down previously from $11.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, August 6th. Morgan Stanley set a $8.60 price target on Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Jones Trading downgraded Y-mAbs Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald set a $8.60 price target on Y-mAbs Therapeutics and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, August 5th. Eight equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Reduce&#34; and an average price target of $9.62.</p>
<div class="lb-trans"><p>一些研究公司最近对 YMAB 发表了评论。Oppenheimer 在 8 月 5 日的报告中将 Y-mAbs Therapeutics 的评级从 “跑赢大盘” 下调至 “市场表现”。HC Wainwright 在 8 月 6 日的报告中重申了 “中性” 评级，并对 Y-mAbs Therapeutics 的股票设定了 8.60 美元的目标价（之前为 11.00 美元）。摩根士丹利在 8 月 5 日的研究报告中对 Y-mAbs Therapeutics 设定了 8.60 美元的目标价。Jones Trading 在 8 月 5 日的研究报告中将 Y-mAbs Therapeutics 的评级从 “强烈买入” 下调至 “持有”。最后，Cantor Fitzgerald 在 8 月 5 日的研究报告中对 Y-mAbs Therapeutics 设定了 8.60 美元的目标价，并给予该股票 “中性” 评级。八位股票研究分析师对该股票给予了 “持有” 评级，两位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “减持”，平均目标价为 9.62 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Y-mAbs Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Y-mAbs Therapeutics 的最新股票分析</strong></p>
</div><h2>About Y-mAbs Therapeutics</h2>
<div class="lb-trans"><h2>关于 Y-mAbs Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.</p>
<div class="lb-trans"><p>Y-mAbs Therapeutics, Inc.是一家商业阶段的生物制药公司，专注于开发和商业化抗体基础的治疗产品，以治疗美国及国际上的癌症。它提供 DANYELZA，一种与粒细胞 - 巨噬细胞集落刺激因子联合使用的单克隆抗体，用于治疗骨髓或骨中复发或难治性高风险神经母细胞瘤的儿童患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Y-mAbs Therapeutics</li>
<li>How to Profit From Growth Investing</li>
<li>MarketBeat Week in Review – 08/25 - 08/29</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Improving Fundamentals Drive New Buybacks for 3 Strong Performers</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>3 Reasons Gartner Could Be the Best Buy of Q3</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Y-mAbs Therapeutics</li>
<li>如何从成长投资中获利</li>
<li>MarketBeat 周回顾 – 08/25 - 08/29</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>改善基本面推动三只强劲表现者的新回购</li>
<li>英国市场假期是什么？如何投资和交易</li>
<li>Gartner 可能是第三季度最佳买入的三个理由</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding YMAB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 YMAB 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Y-mAbs Therapeutics, Inc.（NASDAQ:YMAB - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WU1BQg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=YMAB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Y-mAbs Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Y-mAbs Therapeutics 吗？</h2>
</div><p>Before you consider Y-mAbs Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Y-mAbs Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场意识到之前……而 Y-mAbs Therapeutics 并不在名单上。</p>
</div><p>While Y-mAbs Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Y-mAbs Therapeutics 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

Acorn Capital Advisors LLC 提升了 Y-mAbs Therapeutics, Inc. 的 $YMAB 股份